Oncology Institute, Inc. Files 10-K/A Amendment
Ticker: TOIIW · Form: 10-K/A · Filed: Apr 22, 2024 · CIK: 1799191
| Field | Detail |
|---|---|
| Company | Oncology Institute, Inc. (TOIIW) |
| Form Type | 10-K/A |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $11.50, $0.55 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, Oncology Institute, TOI, TOIIW, SEC Filing
TL;DR
<b>Oncology Institute, Inc. has filed an amended 10-K report for the fiscal year 2023, detailing its common stock and warrants trading on Nasdaq.</b>
AI Summary
Oncology Institute, Inc. (TOIIW) filed a Amended Annual Report (10-K/A) with the SEC on April 22, 2024. Oncology Institute, Inc. filed an amended 10-K report for the fiscal year ended December 31, 2023. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol TOI. Redeemable warrants, exercisable for one share of common stock at $11.50 per share, also trade on Nasdaq under TOIIW. The company was formerly known as DFP HEALTHCARE ACQUISITIONS CORP. and changed its name on January 8, 2020. The filing is an annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
For investors and stakeholders tracking Oncology Institute, Inc., this filing contains several important signals. This amendment provides updated information for the fiscal year 2023, which is crucial for investors to assess the company's current financial standing and operational status. The inclusion of details about common stock (TOI) and redeemable warrants (TOIIW) trading on Nasdaq highlights the company's public market presence and potential for shareholder value.
Risk Assessment
Risk Level: low — Oncology Institute, Inc. shows low risk based on this filing. The risk is low as this is a routine amendment to a 10-K filing, indicating standard reporting procedures rather than immediate material events.
Analyst Insight
Investors should review the amended 10-K for any new disclosures or clarifications that may impact their investment thesis.
Key Numbers
- 2023-12-31 — Fiscal Year End (Report period)
- 2024-04-22 — Filing Date (Date of amendment filing)
- 001-39248 — Commission File Number (SEC file number)
- 84-3562323 — IRS Employer Identification No. (Company's IRS number)
- 11.50 — Warrant Exercise Price (Price per share for warrant exercise)
Key Players & Entities
- Oncology Institute, Inc. (company) — Registrant name
- DFP HEALTHCARE ACQUISITIONS CORP. (company) — Former company name
- The Nasdaq Stock Market LLC (company) — Exchange where securities are registered
- TOI (company) — Trading symbol for Common Stock
- TOIIW (company) — Trading symbol for Redeemable warrants
- 11.50 (dollar_amount) — Exercise price for redeemable warrants
FAQ
When did Oncology Institute, Inc. file this 10-K/A?
Oncology Institute, Inc. filed this Amended Annual Report (10-K/A) with the SEC on April 22, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Oncology Institute, Inc. (TOIIW).
Where can I read the original 10-K/A filing from Oncology Institute, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Oncology Institute, Inc..
What are the key takeaways from Oncology Institute, Inc.'s 10-K/A?
Oncology Institute, Inc. filed this 10-K/A on April 22, 2024. Key takeaways: Oncology Institute, Inc. filed an amended 10-K report for the fiscal year ended December 31, 2023.. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol TOI.. Redeemable warrants, exercisable for one share of common stock at $11.50 per share, also trade on Nasdaq under TOIIW..
Is Oncology Institute, Inc. a risky investment based on this filing?
Based on this 10-K/A, Oncology Institute, Inc. presents a relatively low-risk profile. The risk is low as this is a routine amendment to a 10-K filing, indicating standard reporting procedures rather than immediate material events.
What should investors do after reading Oncology Institute, Inc.'s 10-K/A?
Investors should review the amended 10-K for any new disclosures or clarifications that may impact their investment thesis. The overall sentiment from this filing is neutral.
How does Oncology Institute, Inc. compare to its industry peers?
The Oncology Institute, Inc. operates within the healthcare sector, specifically focusing on oncology services.
Are there regulatory concerns for Oncology Institute, Inc.?
The company is required to comply with SEC regulations, including filing annual reports (10-K) and amendments (10-K/A) under the Securities Exchange Act of 1934.
Risk Factors
- Reporting Obligations [low — regulatory]: The company is subject to Section 13 or 15(d) of the Securities Exchange Act of 1934, requiring regular filings.
Industry Context
The Oncology Institute, Inc. operates within the healthcare sector, specifically focusing on oncology services.
Regulatory Implications
The company is required to comply with SEC regulations, including filing annual reports (10-K) and amendments (10-K/A) under the Securities Exchange Act of 1934.
What Investors Should Do
- Review the full amended 10-K filing for detailed financial and operational information.
- Monitor Nasdaq for trading activity of TOI and TOIIW.
- Assess any changes or clarifications made in the amendment compared to the original 10-K filing.
Key Dates
- 2023-12-31: Fiscal Year End — The period covered by the annual report.
- 2024-04-22: Filing Date — Date the amended 10-K was filed with the SEC.
Year-Over-Year Comparison
This is an amended 10-K filing (10-K/A), indicating updates or corrections to the original annual report for the fiscal year 2023.
Filing Stats: 4,638 words · 19 min read · ~15 pages · Grade level 11.7 · Accepted 2024-04-22 16:30:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TOI The Nasdaq St
- $11.50 — mon stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Mark
- $0.55 — gistrant, based on the closing price of $0.55 per shares of the Registrant's common s
Filing Documents
- toi_10ka.htm (10-K/A) — 579KB
- ex31x1.htm (EX-31.1) — 3KB
- ex31x2.htm (EX-31.2) — 3KB
- 0001079973-24-000580.txt ( ) — 907KB
- toi-20231231_pre.xml (EX-101.PRE) — 27KB
- toi-20231231.xsd (EX-101.SCH) — 4KB
- toi-20231231_def.xml (EX-101.DEF) — 28KB
- toi-20231231_lab.xml (EX-101.LAB) — 39KB
- toi_10ka_htm.xml (XML) — 9KB
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance 5
Executive Compensation
Item 11. Executive Compensation 14
Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 20
Certain Relationships and Related Transactions, and Director Independence
Item 13. Certain Relationships and Related Transactions, and Director Independence 22
Principal Accountant Fees and Services
Item 14. Principal Accountant Fees and Services 23 Part IV 24
Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statement Schedules 24
Signatures
Signatures 25 4 Table of Contents PART III
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance The following table sets forth information regarding our directors, director nominees and executive officers, including their ages as of April 15, 2024: Name Age Position(s) Directors Richard Barasch 70 Chairman of the Board Brad Hively 45 Vice Chairman of the Board Maeve O'Meara Duke 42 Director Karen Johnson 63 Director Mohit Kaushal 45 Director Gabriel Ling 42 Director Anne McGeorge 63 Director Mark Pacala 68 Director Daniel Virnich 45 Director Nominee Executive Officers Daniel Virnich 45 Chief Executive Officer Mihir Shah 45 Chief Financial Officer Yale Podnos 53 Chief Medical Officer Jeremy Castle 39 Chief Operations Officer Information about our Directors: Richard Barasch has served as our Chairman since the formation of the Company in November 2019. He served as the Chairman, President and Chief Executive Officer of DFP Healthcare Acquisitions Corp. ("DFP") from its formation in November 2017 until the closing of its initial business combination with AdaptHealth Corp in November 2019. Since the merger, Mr. Barasch has continued to serve as AdaptHealth's Chairman, and since July 2023, its Interim Chief Executive Officer. In addition, he served as Executive Chairman of Deerfield Healthcare Technology Acquisitions Corp. ("DFHT") until the closing of its initial business combination with IMC Medical Group Holdings, LLC ("IMC") and CareMax Medical Group, L.L.C. (together with IMC, "CareMax"), which Mr. Barasch served as Executive Chairman until February 2022. Mr. Barasch was Chief Executive Officer of Universal American Corp., a publicly-traded health insurance and services company focused on the senior market and government programs, from 1995 until Universal American's acquisition by WellCare Health Plans in May 2017. He also was a founding partner of RAB Ventures LLC, formed to invest in growth healthcare companies. He serves on the Bo